Cantor Fitzgerald Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $220.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective increased by Cantor Fitzgerald from $150.00 to $220.00 in a report issued on Monday, Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the stock. Needham & Company LLC raised their price target on shares of Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the company a buy rating in a research report on Monday, June 24th. Bank of America raised their price target on shares of Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the company a buy rating in a research report on Tuesday, June 25th. UBS Group raised their price target on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a buy rating in a research report on Friday, June 28th. HC Wainwright restated a buy rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Finally, Evercore ISI lifted their target price on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an outperform rating in a research report on Tuesday, June 25th. Eight analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus target price of $256.73.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $237.88 on Monday. The firm’s fifty day simple moving average is $197.28 and its 200-day simple moving average is $172.50. The company has a market capitalization of $30.09 billion, a P/E ratio of -88.76 and a beta of 0.37. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $263.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. The firm’s revenue was up 54.8% on a year-over-year basis. During the same period last year, the company earned ($1.40) earnings per share. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals will post -3.99 earnings per share for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 7,093 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $19,168,101. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Yvonne Greenstreet sold 7,093 shares of the company’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $261.00, for a total value of $1,851,273.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $19,168,101. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the transaction, the director now owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The disclosure for this sale can be found here. Insiders sold 74,450 shares of company stock worth $15,287,984 in the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ALNY. Raymond James & Associates raised its position in Alnylam Pharmaceuticals by 15.1% in the 4th quarter. Raymond James & Associates now owns 14,286 shares of the biopharmaceutical company’s stock valued at $2,734,000 after purchasing an additional 1,875 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Alnylam Pharmaceuticals by 110.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 14,166 shares of the biopharmaceutical company’s stock valued at $2,712,000 after purchasing an additional 7,436 shares during the last quarter. Altfest L J & Co. Inc. raised its position in Alnylam Pharmaceuticals by 29.7% in the 4th quarter. Altfest L J & Co. Inc. now owns 2,073 shares of the biopharmaceutical company’s stock valued at $397,000 after purchasing an additional 475 shares during the last quarter. Values First Advisors Inc. raised its position in Alnylam Pharmaceuticals by 7.3% in the 4th quarter. Values First Advisors Inc. now owns 6,983 shares of the biopharmaceutical company’s stock valued at $1,337,000 after purchasing an additional 476 shares during the last quarter. Finally, Quent Capital LLC raised its position in Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 123 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.